gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MYGNHealthcareDiagnostics

Myriad Genetics Inc (MYGN)

$6.02−0.33%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$6.02▼ 6.81% in range
Nov 4, 2025Low $2.86 · High $7.91Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Myriad Genetics closed at $6.02 on Nov 4, down 0.33%, 26.4% below its 52-week closing high. Volume of 2.1M shares was 0.68× its 20-day average (below normal).

Split-adjusted performance: +40.7% over one month, +46.5% over six months, -26.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $190.70M, down 10.5% from a year earlier, with a net margin of -22.7%.

Short interest was 9.3M shares at the Oct 15 settlement, up 8.4% from the prior report (10.1% of float, 5.3 days to cover).

Market cap$575.8M95.6M shares
Revenue · quarter$190.7M−10.5% YoY
Diluted EPS$-0.46—
P/E · TTM—P/S 0.7×
Net margin-22.7%Gross 66.6%
Dividend yieldNone
52-week range2.86 – 8.18−26.4% from high
Volume2.1M0.68× 20-day avg
Volatility · 60d85.0%Annualised
Short % of float10.1%5.3 days to cover
Net cash-$5.5MCash $115.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.2%1M +40.7%3M +89.3%6M +46.5%YTD −2.1%1Y −26.4%3Y −58.4%5Y −80.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum93
Revenue growth33
Net margin58
Value (low P/E)—
Size50

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short9.3M+8.4% vs prior
Days to cover5.3Settled Oct 15
% of float10.1%
Short vol. 10d33.9%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8M
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare
QDELQuidelOrtho$14.35+1.85%+30.9%+2.8%−14.7%—$984.1MCompare
NTLAIntellia Therapeutics$12.31+3.79%−11.1%−46.2%−1392.3%—$1.72BCompare
CLDXCelldex Therapeutics$29.93+0.74%−13.0%−97.0%−334104.5%—$2.35BCompare
NEOGNeogen$12.46+2.98%+35.7%+6.5%−5.3%—$2.72BCompare
ICCCImmucell$10.37+1.17%+19.7%+11.5%25.5%119.6$94.2MCompare
IMDXInsight Molecular Diagnostics$2.65−3.28%−47.3%−53.9%−4711.3%—$86.7MCompare

News about Myriad Genetics

All news →
Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 7h ago▲ PositiveMyriad Genetics Appoints Vishal Sikri Executive Vice President - CommercialGlobeNewswire Inc. · Sep 16, 2026▲ PositiveMYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the FirmGlobeNewswire Inc. · Aug 7, 2026▼ NegativeMYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudGlobeNewswire Inc. · Aug 6, 2026▼ NegativeActress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her LifeGlobeNewswire Inc. · May 15, 2026▲ Positive

Quick answers

What does Myriad Genetics do?
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights.
What is MYGN's market cap?
$575.81M, based on the Nov 4 close of $6.02.
Does Myriad Genetics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MYGN is sold short?
9.3M shares, 10.1% of float, as of Oct 15, 2026.
What sector is MYGN in?
Healthcare, in the Diagnostics industry.

About Myriad Genetics

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

HQ: Salt Lake City, UT2,700 employeesListed Oct 6, 1995myriad.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology